Rafarma (OTC: RAFA) is pleased to announce commencement of production of the antibiotic Ceftriaxone. Ceftriaxone treats inflammatory infections of the organs of the abdominal cavity, including peritonitis, as well as inflammatory diseases of the gastrointestinal and bile-excreting tracts. According to 2011 official statistics, the market for Ceftriaxone in Russia is estimated at more than $51 million (USD) annually. As a participant in the Russian Federal Program for Domestic-Produced Vital Drugs, Rafarma intends to take as much as 50% of the Russian market for Ceftriaxone.
ZAO SIA International and the Russian national retail chain OAO A5 Pharmacy Ltd. have entered into long-term distribution contracts giving Rafarma an overnight national presence in the Russian Federation retail pharmaceutical market.
CEO David Anderson stated, "Rafarma's increase in production and penetration of market share becomes even more assured with the 17 national distributors we have signed to long term agreements. These contracts were an integral part of Rafarma’s expansion plan and will play a vital role in the expansion of operations. Rafarma has positioned itself to become one of the five leading pharmaceutical companies in the Russian Federation. "
Mr. Anderson went on to say, "The agreements with these drug store chains and pharmaceutical supply companies moves Rafarma in a very positive direction and also shows the respect these companies have for Rafarma. I am extremely pleased that we get to work with such qualified partners that have the confidence in Rafarma to lock in long-term contracts."
ABOUT CEFTRIAXONE:
Ceftriaxone is produced for injections and will be packaged in 10 ml. bottles with single gram dosages. Ceftriaxone shall be produced in Unit 2 of Rafarma?s Terbuni plant. Unit 2 specializes in the production of cephalosporin-based products and bottle-packaged injection products.
ABOUT RAFARMA PHARMACEUTICALS, INC.:
Rafarma Pharmaceuticals is a Russia-based multi-product pharmaceutical company producing generic antibiotics and specialty pharmaceuticals, in addition to its own line of proprietary products that are approved by the Ministry of Health of the Russian Federation.
Safe Harbor Statement
Matters discussed in this press release contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. When used in this press release, the words "anticipate," "believe," "estimate,", "may," "intend," "expect" and similar expressions identify such forward-looking statements. Actual results, performance or achievements could differ materially from those contemplated, expressed or implied by the forward-looking statements contained herein. These forward-looking statements are based largely on the expectations of the Company and are subject to a number of risks and uncertainties. These include but are not limited to: the impact of economic, competitive and other factors affecting the Company and its operations, markets, product, and distributor performance.
SOURCE: Rafarma Pharmaceuticals, Inc.